Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

To evaluate the efficacy, safety, recurrence site, recurrence pattern and resistance mechanism of 160mg furmonertinib as first-line therapy in advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR classical mutations(19Del or L858R).

Trial Details

NCT ID
NCT06674343
Phase
PHASE3
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Furmonertinib
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • ≥ 18 years old, Male or Female
  • Histologically or cytologically confirmed locally advanced or metastatic lung adenocarcinoma not amenable to curative surgery or radiotherapy;
  • Patients have been confirmed by local laboratory to have one of the following EGFR mutations: 19Del or L858R (single or compound)
  • Patients had locally advanced NSCLC or metastatic NSCLC without any systemic antitumor therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →